Pharmaceutical Industry Trends for 2024 So Far

As 2024 unfolds, there are certain areas of focus in our industry that we should continue to watch. I will begin by highlighting key industry themes, followed by a discussion on developments in regions around the world, therapies, companies, and regulatory trends. It is starting off to be a great year for the pharmaceutical industry and there are a lot of things to keep in mind.

Reflecting on 2023, we observed some persistent themes. Sterile manufacturing and microbiology have continued to grow, with manufacturing and testing rising by 12 to 20% CAGR.  Continuous manufacturing and digital transformation are changing the manufacturing landscape, prompting many generic companies to consider investing in new technologies to reduce downtime and address product quality issues from legacy equipment and facilities.  This theme is critical as it directly impacts the quality of the medicines supply chain.

Another concerning theme we continue to see is the shortage of skilled labor.  Manufacturers are likely hiring a different type of employee these days, one who requires specific education and training to be effective, proficient, and engaged enough to stay and advance their career in the industry. Like other sectors, pharmaceutical manufacturers are struggling to attract the right talent, with 80 percent of facilities having difficulty finding candidates with the necessary skills.  Almost half of the leaders in manufacturing companies and human resource professionals in the pharma sector identify talent scarcity as a major pain point.  Not only is the “Great Resignation” affecting staffing, but the expectations of new talent are also changing.  These employees value work-life balance and increasingly prefer work at home options, reducing the pool of qualified candidates.  Gone are the days when entry-level employees simply worked their way up within a company. New employees now expect different approaches to learning and growth.  Integrating scalable tools like Virtuosi into training programs is one strategy, and there may even be potential for AI to replace certain roles on the production line, presenting a double-edged sword.

Competition is intensifying among the top 20 pharma companies.  Notably, companies investing heavily in R&D are the ones to watch, as these investments are expected to shape the industry over the next decade. Increased economic pressures and the Inflation Reduction Act (IRA) are prompting consolidation among smaller firms unable to match this spending, allowing major R&D investors to make substantial gains and reduce competition. Specifically, significant investments are being made in R&D for Alzheimer’s disease, GLP-1/Obesity treatments, and immunology medicines, which have driven growth this year. These areas pose higher risks but face less commercial saturation. Furthermore, biologics—particularly Monoclonal Antibodies, vaccines, and Antibody-Drug Conjugates—are the largest markets.

Lastly, there is an increase in regulatory pressures and more active agency activity following Covid-19.  The FDA, for instance, has moderated its issuance of warning letters in response to medicine shortages, although the number of extensive Form 483 observations is rising.  These are the primary observations so far this year, from Redica.

In addition, the FDA is making a stronger push to implement the Quality Management Maturity (QMM) model in response to drug shortages.  Carla Lundi, Senior Consumer Safety Officer at the FDA, states, “This gets the company to focus on continually improvement and enhanced supply chain reliability through strategic integration of business decisions and manufacturing operations with quality practices and technological advancements.”

To summarize, 2024 is proving to be both a remarkable and challenging year for the pharmaceutical industry.  Challenges foster growth, highlighting the need for improvement and adaptation in certain areas. Aseptic processing and testing are expanding, reflecting a significant market focus. The ongoing skilled labor shortage and increasing competition are driving the need for enhanced critical thinking and problem-solving skills. And as always, maintaining a focus on global compliance and regulatory standards remains crucial as we continue into this year and beyond.

If you would like to learn more about Quality Executive Partners and our educational product, Virtuosi, please reach out.  We would love to hear from you.

www.qualityexecutivepartners.com

www.virtuosivr.com

The Crucial Nexus: Data Integrity in Pharmaceutical Manufacturing

Christine Feaster
May 17, 2024

Decoding the Technical Transfer Process in Biotech Manufacturing

Sarah Boynton
April 23, 2024

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Practicing Risk Acceptance

Mark Roache
August 28, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

Crystal Mersh
June 6, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

When is ISO 8 Not ISO 8?

Bob Ferer
May 30, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023